Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI
2015 | journal article
Jump to:Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI
Wolfsgruber, S.; Jessen, F.; Koppara, A.; Kleineidam, L.; Schmidtke, K.; Frölich, L. & Kurz, A. et al. (2015)
Neurology, 84(12) pp. 1261-1268. DOI: https://doi.org/10.1212/wnl.0000000000001399
Documents & Media
Details
- Authors
- Wolfsgruber, Steffen; Jessen, Frank; Koppara, Alexander; Kleineidam, Luca; Schmidtke, Klaus; Frölich, Lutz; Kurz, Alexander; Schulz, Stefanie; Hampel, Harald; Heuser, Isabella; Peters, Oliver; Reischies, Friedel M.; Jahn, Holger; Luckhaus, Christian; Hüll, Michael; Gertz, Hermann-Josef; Schröder, Johannes; Pantel, Johannes; Rienhoff, Otto ; Rüther, Eckart ; Henn, Fritz; Wiltfang, Jens ; Maier, Wolfgang; Kornhuber, Johannes ; Wagner, Michael
- Abstract
- Objective: To test whether, in individuals with mild cognitive impairment (MCI), different measures of subjective cognitive decline (SCD) in the memory domain predict abnormal CSF biomarkers of Alzheimer disease (AD).Methods: We analyzed the multicenter baseline (cross-sectional) data of 245 patients with MCI. SCD was measured quantitatively with the Subjective Memory Decline Scale (SMDS) and qualitatively by assessing particular concerns associated with self-experienced worsening of memory. Logistic regression models were used to examine associations between SCD and abnormal CSF biomarkers, taking into account objective memory impairment, depressive symptoms, and education as covariates.Results: Abnormal CSF β-amyloid 1–42 (Aβ42) and more depressive symptoms were associated with higher SMDS scores and with the report of memory concerns. Risk of abnormal CSF Aβ42 increased by an estimated 57% for a 1-SD increase in SMDS scores and was doubled in patients who had SMDS scores >4 or who reported memory concerns, respectively. In addition, both SCD measures predicted risk of having a biomarker signature indicative of prodromal AD defined as presence of low CSF Aβ42 together with either high CSF tau or CSF phosphorylated tau 181 levels.Conclusions: In MCI, specific aspects of SCD severity and quality are related to CSF biomarkers indicative of AD. This extends findings in pre-MCI samples and calls for an improved operational assessment of SCD in MCI. This might be useful for sample enrichment strategies for increased likelihood of AD pathology.
- Issue Date
- 2015
- Journal
- Neurology
- ISSN
- 0028-3878
- Language
- English